Kura Oncology (KURA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 30. Analyst Jonathan Chang from Leerink Partners remains neutral on the stock and has a $30.00 price target.
Jonathan Chang’s Buy rating for Kura Oncology is anchored on the promising early results from their recent clinical trials for ziftomenib. The combination of ziftomenib with other treatments showed a positive efficacy profile in patients with acute myeloid leukemia, with significant complete response rates. This suggests that ziftomenib could potentially lead the menin inhibitor class due to its high combinability and manageable safety profile, which is critical for its adoption in treating earlier stages of the disease.
Moreover, Chang’s optimistic outlook is bolstered by Kura Oncology’s strategic positioning and the anticipated progress of their clinical development over the next year. The absence of differentiation syndrome and other severe side effects in the early trial stages points to a strong potential for ziftomenib as a treatment option. With further updates expected and a clear path laid out by Kura’s management, Chang’s recommendation reflects confidence in the company’s long-term execution on its development strategy, justifying the raised price target to $30.
In another report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $32.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Kura Oncology (KURA) Company Description:
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
Read More on KURA:
- Kura Oncology’s KOMET-007 Trial Shows Promising Results
- Unusually active option classes on open January 30th
- Kura Oncology to hold a virtual investor event
- Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
- Kura Oncology reports preliminary ziftomenib combination data
